Vascular Ulcers Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Vascular Ulcers Treatment Market Trends and Insights

Rising Prevalence of Diabetes, Chronic Venous Insufficiency and Peripheral Arterial Disease

The vascular ulcers treatment market draws demand from a large and growing diabetes population. In 2024, 589 million adults aged 20 to 79 lived with diabetes worldwide, or 11.11% of this adult population. The number is projected to reach 853 million by 2050, which expands the pool of patients who may require prevention, early assessment, and long-duration wound care. More than 59% of adults aged 30 and older with diabetes did not receive medication in 2022, leaving unmanaged disease concentrated in many low- and middle-income countries where access to early care is less consistent. Chronic venous insufficiency and peripheral arterial disease further complicate healing because they can coexist with diabetes and increase the need for repeated treatment decisions, specialist review, and product use. A 2025 U.S. analysis reported lower-extremity peripheral arterial disease healthcare costs above USD 21 billion annually, largely from hospital care and long-term ischemic wound management, which shows the scale of care associated with severe vascular disease.

Expansion of Advanced Wound Care and Bioengineered Tissue Products

Advanced wound care products are becoming more important when conventional treatment does not close a wound. A 2025 meta-analysis covering 29 randomized controlled trials and 2,255 patients found that cellular and acellular tissue-based products combined with standard care had a pooled odds ratio of 2.9 for complete healing versus standard care alone. This benefit remained across patient age and initial wound-size groups, which makes the evidence relevant to a broad range of difficult-to-heal wounds. The vascular ulcers treatment market therefore has greater scope for biological products in persistent wounds that have not responded to standard compression and dressings. ConvaTec received EU and UK approval for ConvaMatrix, a porcine placenta-derived skin substitute, in September 2025. Wider clinical evidence can move these products from occasional use toward earlier consideration in hospital and outpatient formularies, although suppliers still need to show that higher product costs are matched by appropriate clinical and economic value.

Shift Toward Outpatient, Homecare and Community-Based Wound Management

Homecare settings are projected to record an 8.85% CAGR through 2031 in the vascular ulcers treatment market. Payers are seeking to reduce inpatient bed use and nursing costs when patients can be managed safely outside hospitals, while many patients prefer care that fits daily routines. The change increases the need for products that patients or caregivers can apply correctly, since compression treatment is effective only when it is used consistently and at the intended pressure. A 2025 clinical evaluation found that real-time pressure monitoring raised applications within the target compression range from 39% to 66%. It also improved daily wound-area reduction from 1.31% to 2.3%, indicating that monitoring can address a practical limitation of self-managed care. North America and Europe have the payer incentives, telehealth systems, and remote monitoring capacity that support this care model, while other regions may adopt these approaches more gradually as outpatient infrastructure develops.

Growth of Multidisciplinary Limb-Salvage and Vascular-Wound Care Pathways

Multidisciplinary care is changing purchasing decisions at high-volume wound centers. A 2025 review found that multidisciplinary clinics increased amputation-free survival from 35.4% to 64% and reduced healing time from 610 days to 426.1 days. A 2025 BEST-CLI analysis also found that formally organized multidisciplinary teams independently reduced major-amputation risk^{[1]“Characteristics of Multidisciplinary Limb Preservation Teams and Their Impact on Outcomes in the BEST-CLI Trial,” Journal of Vascular Surgery, doi.org}. These teams usually include vascular surgeons, podiatrists, plastic surgeons, and advanced practice wound-care providers, allowing a wound’s vascular cause and treatment plan to be assessed together. Their formulary committees, rather than individual clinicians, increasingly determine access to dressings and biologics at high-volume sites. The vascular ulcers treatment market favors suppliers that can provide strong comparative clinical evidence for these institutional reviews and can fit products into coordinated pathways that span assessment, treatment, and follow-up.

High Cost of Advanced Dressings, Biologics and Therapy Devices

The cost of advanced care can restrict use even when clinical evidence is favorable. Skin substitutes can cost more than USD 1,000 per application, while coverage for repeated use differs widely by payer and by the documentation required for a non-healing wound. Paul Hartmann AG reported EUR 623.6 million (USD 710.35 million) in wound-care revenue in 2025 and organic growth of 2.6%. Germany and France experienced direct revenue pressure from coverage reductions, demonstrating how reimbursement changes can affect even established suppliers. These conditions show that price and health-economic evidence must accompany clinical development and product launches. The vascular ulcers treatment market may face slower adoption in systems that are tightening reimbursement for premium wound products, particularly when less costly compression and dressing options remain available for earlier-stage care. The vascular ulcers treatment market consequently rewards suppliers that can support coverage decisions with clear evidence.

Compression Nonadherence Caused by Pain, Heat, Dexterity Limitations and Poor Fit

Long-term compression adherence was only 39.9% among patients in a 2025 concordance study, including people whose ulcers had healed but remained at risk of recurrence. A separate 2025 randomized controlled trial found that a structured multidisciplinary education program raised 3-month adherence from 26.8% to 63%. Maintaining that improvement requires continuing clinical involvement that many community settings cannot provide, especially when pain, heat, limited hand dexterity, and poor fit make compression difficult to use. A 2025 Delphi study identified 105 factors related to concordance, including comfort, clinician attributes, access, and motivation. Compression wraps may be the only practical option for some patients, although comparative effectiveness evidence remains mixed^{[2]National Institute for Health and Care Excellence, “Compression Products for Treating Venous Leg Ulcers: Late-Stage Assessment,” NICE, nice.org.uk}. This challenge expands the need for education, fit assessment, pressure monitoring, and follow-up alongside product supply, rather than relying on the device alone. The vascular ulcers treatment market can therefore extend beyond products into support for correct and sustained use.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Ulcer Type: Diabetic Ulcers Are Growing Faster Than Venous Ulcers

Venous ulcers held 45.31% of revenue in 2025, supported by chronic venous insufficiency and long treatment cycles. Their prevalence in older Western populations provides a steady demand base for dressings, compression, and follow-up care. Active venous leg ulcer prevalence was 0.1% in the general population, but it rose to 4% to 5% among adults older than 80^{[3]“Das venöse Ulcus cruris,” Springermedizin, springermedizin.de}. This age pattern makes population aging important to the vascular ulcers treatment market. Arterial, neurotrophic, and mixed vascular ulcers require different clinical decisions and can lengthen treatment. Mixed ulcers require confirmation of arterial sufficiency before compression is used safely.

Diabetic ulcers are projected to grow at a 7.58% CAGR through 2031. Diabetic foot ulcers affect 12% to 25% of adults with diabetes and account for 80% to 90% of lower-extremity amputations in the United States. The 2024 global diabetes population of 589 million creates a growing pathway toward established vascular ulcers. Diabetic ulcers may exceed venous ulcers in growth momentum before 2031. Suppliers need portfolios that address ischemia, infection risk, and prolonged healing without becoming too narrowly focused.

By Product Type: Biological Products Are Changing a Dressings-Led Product Mix

Advanced wound dressings held 38.24% of product revenue in 2025. They remain central to wound-bed preparation and daily exudate management across hospitals, clinics, and homes. Their broad use means they remain a core volume category even as biological products expand. Compression bandages, wraps, stockings, garments, pumps, and devices remain integral to venous ulcer treatment. NICE found that four-layer bandages and two-layer hosiery remained the most cost-effective compression configurations in the United Kingdom. That finding can constrain premium pricing for wraps and self-managed devices.

Skin substitutes and biological matrices are projected to expand at an 8.22% CAGR through 2031. A 2025 meta-analysis of 29 randomized controlled trials and 2,255 patients found an odds ratio of 2.9 for complete healing when tissue-based products were combined with standard care. The result remained consistent across age and wound-size groups. ConvaMatrix received EU and UK approval in September 2025, adding a porcine placenta-derived option for advanced wound management. The vascular ulcers treatment market needs adequate wound-bed preparation before high-cost biological products can deliver their intended value. Debridement and wound-cleansing products therefore remain stable contributors across the product mix.

By Wound Stage: Moderate Ulcers Have the Strongest Growth Profile

Superficial or mild ulcers accounted for 38.14% of value in 2025. Their volume reflects early presentation and a lower treatment cost per episode. Compression alone can close many venous ulcers at this stage. This limits the use of higher-cost products in uncomplicated cases. Moderate ulcers are projected to grow at a 7.22% CAGR through 2031. The vascular ulcers treatment market size for moderate ulcers expands when patients do not respond to first-line compression and need advanced dressings or skin substitutes.

Moderate ulcers mark the point at which treatment can move from over-the-counter dressings to prescription biological products. Formulary access and clinical evidence then carry more weight than price alone. Deep or severe ulcers, infected ulcers, and ischemic or neuro-ischemic ulcers require high-acuity care. These patients often need vascular surgeons, podiatrists, and wound-care nurses working together. A 2025 BEST-CLI analysis found that multidisciplinary chronic limb-threatening ischemia teams reduced major-amputation risk independently of revascularization. This favors evidence-supported product platforms instead of commodity alternatives.

By End User: Homecare Is Expanding Beyond Hospital-Based Treatment

Hospitals held 45.21% of end-user revenue in 2025. They remain the main treatment and procurement centers for moderate-to-severe vascular ulcers. Formulary decisions at high-volume hospital systems shape use across wound clinics and ambulatory surgical centers. Standardized group purchasing organization agreements can extend this influence across affiliated settings. Specialty wound-care clinics are becoming more important for complex chronic limb-threatening ischemia cases. The vascular ulcers treatment industry benefits when products meet the evidence requirements of these multidisciplinary centers.

Homecare settings are projected to grow at an 8.85% CAGR through 2031. Payer-led discharge planning, self-management preferences, and clinician-independent compression systems support this change. A 2024 Indian pilot study assessed an adjustable compression wrap in 7 patients with open venous leg ulcers. Median volume reduction reached 34.5 cc within 4 hours of self-application. Ambulatory surgical centers are also expanding as sites for debridement and minor biologic applications. These settings spread procurement beyond the hospital pharmacy model and require manufacturers to support several care pathways.

By Distribution Channel: Digital Sales Are Growing Alongside Hospital Pharmacy Control

Hospital pharmacies held 49.56% of channel revenue in 2025. They control access to many advanced products through formulary decisions and group purchasing organization contracts. MiMedx launched G4Derm Plus in May 2026 with agreements involving Premier and Vizient. The launch shows the importance of national hospital network access for biological product entrants. Retail pharmacies remain important for over-the-counter dressings and compression products. They are especially relevant when patients independently manage mild-to-moderate venous ulcers.

Online pharmacies and e-commerce are projected to grow at an 8.55% CAGR through 2031. Digital access gives patients more product information and peer feedback before they select dressings or compression products. This can create a direct consumer opportunity for brands. It can also create clinical risk when a patient selects an unsuitable product without clinician guidance. The vascular ulcers treatment market needs both direct-to-consumer capability and traditional hospital distribution in settings where digital purchasing grows. This mix can change how suppliers present product information, replenishment options, and patient support.

Geography Analysis

North America held 40.61% of revenue in 2025. Its specialist infrastructure and reimbursement pathways support adoption of advanced products in the vascular ulcers treatment market. The region combines specialist wound centers, hospital procurement systems, and outpatient payment structures that support the use of advanced products. The Centers for Medicare & Medicaid Services revised the Wound and Ulcer Care LCD L38902 effective September 2025. It maintained coverage for medically necessary outpatient debridement, advanced dressings, and device therapies. Smith+Nephew launched ALLEVYN COMPLETE CARE Foam Dressing in the United States in March 2026. MiMedx launched CHORIOFIX in the United States in March 2026 through national distribution. These launches illustrate why the vascular ulcers treatment market remains an important launch setting for suppliers of premium wound products.

Europe is the second-largest regional area, supported by chronic venous disease across Germany, the United Kingdom, France, Italy, and Spain. The vascular ulcers treatment market depends on established care infrastructure in these countries, but patient access and reimbursement rules differ widely. A German claims analysis of 16,615 insured patients with venous leg ulcers found that 25% did not receive compression therapy during a 5-year observation period. This gap remains despite compression being the first-line guideline approach. Paul Hartmann reported direct coverage-related pressure in Germany and France during 2025. EU Medical Device Regulation requirements raise the clinical evidence threshold for biologics and advanced dressings. These requirements favor companies with established European regulatory programs and can narrow access for new suppliers.

Asia-Pacific is projected to grow at an 8.25% CAGR through 2031. Japan’s population aged 65 and older accounted for 29% of the national total, adding to venous leg ulcer and pressure injury caseloads. China’s venous leg ulcer prevalence was 1.5%, while its absolute peripheral arterial disease case count continued to increase despite a plateau in standardized prevalence rates. These demographic and disease patterns give the vascular ulcers treatment market a broader base for long-term growth in the region. India is the fastest-growing country in the region, supported by rising diabetes incidence and broader health coverage in tier-2 and tier-3 cities. Mölnlycke formed a joint venture with Zhende Medical in China in May 2026, showing the importance of local distribution partnerships. GCC private hospital networks support advanced product adoption, while parts of Africa, Brazil, Argentina, and other South American countries face uneven access, economic volatility, or both.